AngioGenex, Inc. (fka AGGX)

[e-ore]

.20 x .30 now

From their website which is now "under construction."
AngioGenex is a biopharmaceutical company formed to pursue the discovery and development of proprietary products for the treatment, diagnosis and prognosis of cancer. While there are numerous companies that have the same objective, none have the unique, patented technology that is being exploited by AngioGenex.
The target of the AngioGenex drug discovery effort is a previously unrecognized biological process necessary to support tumor growth that emerged from one of the most famous cancer laboratories, Memorial Sloan Kettering Cancer Center, NYC. Dr. Robert Benezra, a distinguished member of this institute, discovered that certain genes (Id genes) are actively involved in fetal growth and can be inappropriately activated in the adult to support the growth and spread of tumors. He showed that tumor growth is markedly inhibited if these genes or their proteins are even partially inactivated.
In collaboration with Dr. Benezra, AngioGenex has successfully pursued the discovery and development of molecules that inhibit the Id proteins and block tumor growth in animals. This research confirms that the Id genes are the controlling, master genes, in a unique and previously unknown process that is required for the growth and spread of tumors. A profound inhibition of tumor growth is demonstrated in animals that either have the Id genes deleted by genetic manipulation or are treated with an anti-Id drug (See Figure below).
An important finding is that the Id genes are structurally almost identical in humans as in animals suggesting that the anti-tumor effects of Id drug observed in animals will also occur in humans."

The Robert Benezra lab at Memorial Sloan Kettering
https://www.mskcc.org/research-areas/labs/robert-benezra

A/S is 150,000,000 Last known outstanding 21,302,906 as of 11/27/2009

Dr. Benezra a director, chief science officer, and shareholder of AGGX